Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof

Abstract

The invention provides a traditional Chinese medicine preparation for treating immune thrombocytopenia (ITP) and a preparation method thereof. The traditional Chinese medicine preparation comprises the following components in parts by weight: 1 part of selaginella tamariscina, 1-2 parts of acanthopanax, 1-2 parts of morinda officinalis, 1-2 parts of dandelion, 1-2 parts of pseudo-ginseng, 1-2 parts of spatholobus stem, 1-2 parts of white peony root, 1-2 parts of angelica, 1-2 parts of bighead atractylodes rhizome, 1-2 parts of red sage root, 1-2 parts of radix rehmanniae, 1-2 parts of radix astragali, 1-2 parts of dangshen, 1-2 parts of agrimony and 1-2 parts of dodder. From the perspective of modern pharmacological research, the medicines contained by the traditional Chinese medicine preparation of the invention have the effects of regulating immunity, reducing platelet destruction, promoting thrombopoiesis, reducing capillary permeability and the like, thereby achieving the purpose of treating ITP. The medicines are compatible, the formula is simple and complete and hits the pathogenesis, and the medicines play the effects of removing pathogenic heat from blood, removing blood stasis, arresting bleeding, and reinforcing the spleen and kidney, thereby reducing hemorrhage of patients with ITP and alleviating various clinical symptoms.

Description

technical field [0001] The invention relates to a medical preparation containing raw materials derived from plants, animals or minerals and a preparation method thereof, in particular to a traditional Chinese medicine preparation for treating immune thrombocytopenia and a preparation method thereof. Background technique [0002] Immune thrombocytopenic purpura is an immune disease in which autoantibodies bind to platelets, causing increased destruction of platelets, leading to bleeding in the skin, mucous membranes, and internal organs. Thrombocytopenic purpura is a common hemorrhagic disease, accounting for about 70% of hemorrhagic diseases, and has an increasing trend year by year. The first onset is usually under the age of 30. The bleeding is severe at the onset, causing extensive skin and mucous membrane blood spots or ecchymosis or even subcutaneous hematoma. Long-term repeated bleeding can cause anemia and symptoms such as low fever, fatigue, and dizziness. [0003] ...

AI Technical Summary

Problems solved by technology

[0006] At present, the treatment of this disease at home and abroad mainly adopts glucocorticoids, immunosuppression, etc., but there are many problems: 1. Long-term repeated administration is required, and the side effects are quite large, causing complications in the digestive system and cardiovascular system, and even inducing and Aggravated infection

2. Prednisone drugs clinically used to treat thrombocytopenic purpura can easily cause side effects such as Cushing's syndrome, virilization, high blood pressure, and weakened body resistance; immunosuppressant cyclophosphamide drugs can inhibit Hematopoietic function of bone marrow; Danazol drugs have side effects of damage to liver function

3. The curative effect is not good, and 25% of the patients' condition cannot be controlled

Although these varieties play a certain role in the prevention and treatment of this disease, they all have the unfavorable factor of poor pertinence.

Images